Currently servicing as the chairman, chief executive officer and president of Seattle Genetics, Clay Siegall is a serial blogger with a grasp of numerous issues. His blog posts cover a wide variety of topics, which shows his longstanding commitment to knowledge dissemination. One of his latest blog posts tackles the dangerous bird flu virus, which has left many fatalities on its trail especially in China and the greater Asian continent. Dr. Siegall noted that a study that tinkered with the DNA of the H7N9 showed that the virus could become deadly. The study showed that the mutation can lead to faster and easier spread of the virus. The results of the study came out with a few days to go before the federal government lifts a longstanding ban on any researches aimed at mutating the deadly virus. The new development has elicited mixed reactions from the scientific community. A section of scientists condemned the new studies as they have a potential of developing deadlier strains of the virus, which could be released into the population. However, others contend that the studies would lead to better preparations in case the virus mutates in the wild.
Academic and Career Background
Clay Siegall graduated from the University of Maryland with a Bachelor of Science degree in Zoology. He later joined The George Washington University where he graduated with a Doctor of Philosophy degree in Genetics. This provided him with a strong foundation for an award-winning management and investment. Between 1988 and 1991, he worked as a research scientist for National Cancer Institute before moving to Bristol-Myers Squibb Pharmaceutical Research Institute in the same role. He worked at the company up to 1997.
In 1998, he cofounded Seattle Genetics where he has had unbridled success. He has helped the company raise $1.2 billion in capital to finance its cancer research. The company has so far developed an FDA-approved drug, Adcetris with close to a dozen more still within the production pipeline. This has seen him win the Ernest & Young Entrepreneur of the Year Award in 2012. In addition to his duties at Seattle Genetics, Clay Siegall also serves on the board of Washington Roundtable and Alder BioPharmaceuticals among others.